Business Context and Reporting Period
Company: NewGenIVF Group Ltd (NIVF)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: NewGenIVF is an assisted reproductive services (ARS) provider operating clinics in Thailand, Cambodia, and Kyrgyzstan. The company offers In Vitro Fertilization (IVF), egg donation, and surrogacy services. The company completed a business combination with A SPAC I Acquisition Corp. on April 3, 2024, and subsequently underwent a 1-for-20 reverse stock split in February 2025 to regain Nasdaq compliance.
Key Financial Metrics
| Metric | 2024 (US$) | 2023 (US$) |
|---|---|---|
| Total Revenue | 5,433,375 | 5,136,153 |
| Gross Profit | 1,826,894 | 1,681,785 |
| Gross Margin | 33.6% | 32.7% |
| Operating Loss | (1,160,495) | 42,242 |
| Net Loss | (474,101) | 108,418 |
| Cash and Cash Equivalents (Year End) | 457,740 | 54,104 |
| Working Capital | 452,391 | 79,000 |
| Convertible Notes Outstanding | 3,150,000 | 0 |
Note: Net loss includes a non-cash tax benefit of $486,706 from the reversal of an over-provision related to the disposal of a subsidiary.
Material Changes vs. Prior Period
- Revenue Composition Shift: IVF treatment revenue increased 35.1% to $5.43 million, becoming 100% of total revenue. Surrogacy revenue dropped to $0 due to the reorganization and disposal of the Kyrgyzstan subsidiary (First Fertility Bishkek) in December 2024.
- Operating Expenses Surge: Total operating expenses increased 82.2% to $2.99 million. This was driven by $769,820 in professional fees related to the business combination and financing, $123,000 in MicroSort technology license fees, and increased personnel costs.
- Interest Expense: Interest expense rose significantly to $778,656 from $46,179 due to the issuance of convertible notes during the year.
- Geographic Revenue: Thailand revenue grew to 40.0% of total revenue ($2.18M), while Kyrgyzstan revenue declined to 48.9% ($2.66M) as surrogacy operations ceased.
Outlook, Risks, and Contingencies
Going Concern and Liquidity
The filing includes a "Substantial Doubt" regarding the company's ability to continue as a going concern. As of December 31, 2024, the company held only $457,740 in cash. Management plans to bridge liquidity shortfalls through an equity line of credit with White Lion Capital (up to $100M, with ~$7.1M drawn as of report date) and the conversion of outstanding convertible notes.
Listing Status
The company received deficiency notices from Nasdaq regarding minimum bid price and market value requirements. It effected a 1-for-20 reverse stock split in February 2025 and successfully transferred its listing to the Nasdaq Capital Market in late February 2025. A second 1-for-10 reverse stock split was approved in April 2025 to maintain compliance.
Key Risks
- Regulatory Environment: Operations in Thailand, Cambodia, and Kyrgyzstan are subject to complex, evolving regulations regarding medical licensing, surrogacy, and data privacy (e.g., Thailand's PDPA).
- Travel and Geopolitics: Revenue is heavily dependent on international medical tourism, particularly from China. Travel restrictions, political instability, or negative media coverage regarding safety in Southeast Asia could materially impact demand.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of December 31, 2024, citing a material weakness due to a lack of adequately skilled staff with U.S. GAAP knowledge.
- Financing Dependence: The company requires significant capital for growth and operations. Failure to secure additional financing on acceptable terms could lead to insolvency.
Investor Verification Checklist
- Cash Runway: Verify the current cash balance and the status of the $100M equity line of credit with White Lion Capital to assess immediate solvency.
- Debt Conversion: Confirm the conversion status of the $3.15M in convertible notes outstanding at year-end and any new debt issued in 2025.
- Nasdaq Compliance: Monitor the effectiveness of the reverse stock splits in maintaining the $1.00 minimum bid price and market value requirements.
- Internal Control Remediation: Review subsequent filings for evidence of hiring skilled accounting personnel and implementing U.S. GAAP training to address the material weakness.
- Kyrgyzstan Operations: Assess the progress of the new Bi Clinic acquisition and the partnership with BOBCARE to determine if surrogacy revenue can be restored.
- MicroSort Acquisition: Evaluate the integration and commercialization of the MicroSort technology acquired in February 2025.